|Over a week ago|
Neuronetics announces publication of data from NeuroStar Outcomes Registry » 08:1810/1310/13/20
Neuronetics announced that clinical data from its NeuroStar Outcomes Registry, which suggests NeuroStar Advanced Therapy be evaluated as a first-line treatment for Major Depressive Disorder, will be published in the December 2020 print issue of the Journal of Affective Disorders and is available online now. The NeuroStar Outcomes Registry launched in November 2016 for the purpose of collecting and analyzing outcomes data from treatment in real-world clinical settings with Neuronetics' NeuroStar Advanced Therapy, a non-drug, non-invasive option for treating depression. Since its launch, it has grown into the largest registry focused on outcomes for depression treatment. The study authors found that treatment with NeuroStar Advanced Therapy showed robust antidepressant effects, greater than in early open-label studies of transcranial magnetic stimulation. The clinical benefit from NeuroStar Advanced Therapy reported by both patients and clinicians in routine clinical practice compared favorably with alternative interventions for treatment-resistant depression. The authors analyzed two sample sets of more than 5,000 patients across 103 practice sites, evaluating patient-rated and clinician-rated clinical outcomes data from treatment with NeuroStar. The research further validates efficacy results shown in a prior naturalistic study, which showed a 58 percent response rate and 37 percent remission rate on the CGI-S scale. Study highlights include: Self-reported and clinician ratings showed robust antidepressant effects from NeuroStar Advanced Therapy, greater than those in early open-label studies of TMS. Strong efficacy and the low side effect and medical risk profile suggest that NeuroStar Advanced Therapy be evaluated as a first-line treatment for Major Depressive Disorder. Efficacy did not decline with age, and motor threshold was also unrelated to antidepressant effects. Patients who received a larger number of pulses per session had superior outcomes. Females responded more favorably to treatment than males by 5-10%. Remission rates were notably high in both the Intent-to-Treat sample and the Completer sample. Response rates were notably high across self-report and clinician-administered assessments in the Completer sample.
Neuronetics price target raised to $10 from $6 at BTIG » 09:2610/0610/06/20
BTIG analyst Marie…
BTIG analyst Marie Thibault raised the firm's price target on Neuronetics to $10 from $6 and keeps a Buy rating on the shares after hosting investor meetings with its management. The analyst says investors are focusing on how the company's new CEO will reshape its sales and marketing strategy to boost system utilization. Thibault adds that she continues to view Neuronetics as undervalued given its "healthy" balance sheet and market-leading position, with 2021 seen as a potential inflection point for valuation if its new strategy can be executed "effectively".
Neuronetics CCO Dan Guthrie to depart » 08:1310/0510/05/20
Neuronetics announced that Sara Grubbs has been appointed as the company's Vice President, Sales effective immediately. Grubbs brings 15 years of medical device experience to Neuronetics, previously serving in sales leadership and management roles with Revance Aesthetics, Allergan, Ulthera, and Solta Medical as well as other medical device and pharmaceutical companies. On October 5, 2020, the Company also announced that Dan Guthrie, Chief Commercial Officer, would leave Neuronetics at the end of the year to pursue to other professional opportunities. In connection with her hiring on October 5, 2020, the Compensation Committee of the Company's Board of Directors authorized the grant to Ms. Grubbs of restricted stock units representing 75,000 shares of the Company's common stock in accordance with Nasdaq Listing Rule 5635(c)(4), which will vest in three equal annual installments on the anniversary of the grant date, subject to Ms. Grubbs continued employment with the company and subject to Capitalization Adjustments.
Thirteen new option listings and two option delistings on September 30th » 08:3009/3009/30/20
AQB, ESTA, FRG, GMHI, HERO, HGEN, LSPD, NBSE, OCFT, PIC, SPI, STIM, VLDR, ASFI, GRAF
New option listings for…
New option listings for September 30th include AquaBounty Technologies (AQB), Establishment Labs Holdings Inc (ESTA), Franchise Group Inc (FRG), Gores Metropoulos Inc (Class A Stock) (GMHI), Global X Video Games and Esports ETF (HERO), Humanigen Inc (HGEN), Lightspeed POS Inc (LSPD), NeuBase Therapeutics Inc (NBSE), OneConnect Financial Technology Co Ltd (ADS) (OCFT), Pivotal Investment Corporation II (Class A Stock) (PIC), SPI Energy (SPI), Neuronetics Inc (STIM), and Velodyne Lidar Inc (VLDR). Option delistings effective September 30th include Asta Funding Inc (ASFI) and Graf Industrial Corp (Units) (GRAF).
Neuronetics announces 500,000 treatment milestone for Greenbrook TMS » 08:2109/2909/29/20
Neuronetics congratulated Greenbrook TMS, a NeuroStar Advanced Therapy provider with 125 treatment centers across the U.S., for delivering its 500,000th transcranial magnetic stimulation treatment.
Neuronetics presents depression data at Clinical TMS Society events » 08:1609/2209/22/20
Neuronetics will present…
Neuronetics will present clinical data and host virtual educational sessions as part of the Clinical TMS Society's virtual programming. The Clinical TMS Society, a professional association that aims to optimize awareness and accessibility of transcranial magnetic stimulation therapy, is hosting virtual events this year in place of its traditional Annual Meeting, giving attendees a chance to experience educational sessions remotely. As a sponsor, Neuronetics will present a product theater webinar and two virtual poster presentations detailing the company's latest research with NeuroStar Advanced Therapy in bipolar and unipolar depression. On Tuesday, September 29 at 5:30 p.m. PDT, Neuronetics will host a product theater webinar that will address these two topics: Treatment of Bipolar Depression: A Pilot Study-Clinical experience has suggested that NeuroStar Advanced Therapy might be effective for bipolar depression. This presentation will review the existing literature on the efficacy of TMS for bipolar depression and present the findings from a two-center open-label prospective trial of NeuroStar Advanced Therapy in bipolar depression including type I and type II patients. Clinical Outcomes of NeuroStar Advanced Therapy Treatment: The Largest Patient Registry for Depression Treatment with Transcranial Magnetic Stimulation-With more than 9,000 patients across more than 100 private practice locations in the U.S., Neuronetics' Outcomes Registry is the largest registry documenting outcomes for any treatment of Major Depressive Disorder. This presentation will report new findings from the registry about the efficacy of NeuroStar Advanced Therapy in adult patients treated for an episode of MDD in community settings. In addition, the following NeuroStar poster presentations will be on display throughout the duration of the virtual poster session from now through Saturday, October 31: Poster #63: Comparison of Naturalistic Treatment Outcomes with the Standard 38-Minute Protocol vs. Shortened Protocol: A NeuroStar Registry Database Study-Based on a subset analysis of over 7,700 patients from the NeuroStar Outcomes Registry, data demonstrates that efficacy is statistically similar between patients who received the Standard treatment protocol at 38 minutes per session compared to the DASH protocol at 19 minutes per session. Poster #10: Post Marketing Rate of Seizures During Transcranial Magnetic Stimulation Treatment with NeuroStar Advanced Therapy Is Low-In analyzing the seizure rate from post marketing surveillance and from literature related to Neuronetics-sponsored clinical trials, it was found that the rate of seizures reported during TMS treatments with the NeuroStar Advanced Therapy device was even lower than previously estimated.
|Over a month ago|
Neuronetics sees FY20 operating expenses $58M-$60M » 07:3408/0408/04/20
Currently, the Company is…
Currently, the Company is unable to estimate the specific duration or severity of the impact of the COVID-19 pandemic on its financial and operating results and is therefore only providing forward looking guidance as to the Company's projected full year 2020 operating expense. On April 8, 2020 the Company announced a corporate restructuring which would result in operating expenses for the full year 2020 to be in the range of $58 to $60 million, compared to the previously issued guidance of $76 to $78 million. This guidance remains unchanged.
Neuronetics reports Q2 EPS (41c), consensus (51c) » 07:3208/0408/04/20
Reports Q2 revenue $9.7M,…
Reports Q2 revenue $9.7M, consensus $8.2M. "I am excited to join Neuronetics and lead the team on our critical mission to improve mental health for an underserved patient population by expanding access to NeuroStar Advanced Therapy," said Keith J. Sullivan, President and Chief Executive Officer of Neuronetics. "The world is facing an unprecedented challenge with COVID-19. I believe we have taken the right steps to position our company to emerge on the other side of the pandemic in a strong financial position and ready to execute on our business strategy. This quarter was negatively impacted due to the effects of COVID-19; however, our results were favorable to our internal expectations established at the beginning of the quarter. The company experienced positive commercial trends during the second half of the quarter, and we are anticipating these trends will continue through the remainder of the year," said Steve Furlong, Chief Financial Officer of Neuronetics. "Further, the cost reduction efforts announced in April will enable Neuronetics to execute against our operating plan and maintain our robust cash balance."
|Over a quarter ago|
Investors should take 'fresh look' at Neuronetics after CEO hire, says Piper » 19:1207/1407/14/20
Piper Sandler analyst…
Piper Sandler analyst Matt O'Brien reiterated an Overweight rating and $6 price target on Neuronetics after it named Keith Sullivan to the position of CEO, effective immediately. O'Brien said he anticipates the announcement will be well-received by investors given Sullivan's success at ZELTIQ. The analyst added that he remains constructive on the company's ability to weather this period of disruption and further penetrate the multi-billion dollar depression market.
Neuronetics names Keith Sullivan as CEO, effective immediately » 16:1807/1407/14/20
Neuronetics announced that Keith Sullivan has been appointed as the company's President and CEO and has joined the Board of Directors effective immediately. Sullivan brings over three decades of medical device industry experience to the company. He most recently served as Chief Commercial Officer and President, North America, of ZELTIQ Aesthetics.